PharmaShots Weekly Snapshot (June 03 – 07, 2019)


1.STADA to Acquire GSK’s OTC Portfolio for the Expansion of its Consumer Health Business in Europe

Published: Jun 07, 2019 | Tags: STADA, Acquire, GSK, OTC, Portfolio, Expansion, Consumer Health Business, Europe

2. Vertex to Expand its Collaboration with CRISPR Therapeutics to Develop Therapies for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1

Published: Jun 06, 2019 | Tags: Vertex, Expand, Collaboration, CRISPR Therapeutics, Develop, Therapies, Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1

3.Novartis’ LysaKare (arginine hydrochloride/lysine hydrochloride) Solution Receives CHMP’s Positive Opinion for Reduction of Kidney Exposure to Radiation During PPRT with Lutathera

Published: Jun 05, 2019 | Tags: Novartis, LysaKara, arginine hydrochloride/lysine hydrochloride, Solution, Receives, CHMP, Recommendation, Reduction, Kidney Exposure, Radiation, During, PPRT, Lutathera

4.Novartis Reports Histology Data of CFZ533 (iscalimab) in Kidney Transplantation for Extended Survival of Transplanted Organs

Published: Jun 06, 2019 | Tags: Novartis, Reports, Histology Data, CFZ533, iscalimab, Kidney Transplantation, Extended, Survival, Transplanted Organs

5. GSK’s Nucala (mepolizumab) Receives FDA’s Approval for its Two New Self-Administered Methods for Patients with SEA and EGPA

Published: Jun 06, 2019 | Tags: GSK, Nucala, mepolizumab, Receives, FDA, Approval,Two, New, Self-Administered, Methods, Patients, SEA, EGPA

6. AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ELEVATE-TN Trial for Patients with Previously Untreated Chronic Lymphocytic Leukemia

Published: Jun 06, 2019 | Tags: AstraZeneca, Reports, Results, Calquence, acalabrutinib, P-III, ELEVATE-TN, Trial, Patients, Previously, Untreated, Chronic Lymphocytic Leukaemia, CLL

7. Celgene Reports FDA and EMA’s Acceptance of NDA for Ozanimod to Treat Relapsing Forms of Multiple Sclerosis

Published: Jun 06, 2019 | Tags:Celgene, Reports, FDA, EMA, Acceptance, NDA, Ozanimod, Treat, Relapsing, Forms, Multiple Sclerosis

8. Oncolytics Biotech Signs a Clinical Trial Collaboration with Merck KGaA and Pfizer

Published: Jun 05, 2019 | Tags: Oncolytics Biotech, Signs, Co-Development, Clinical Trial, Collaboration, Merck KGaA, Pfizer

9. Enzyvant Reports FDA’s Acceptance of BLA for RVT-802 to Treat Pediatric Congenital Athymia

Published: Jun 06, 2019 | Tags: Enzyvant, Reports, FDA, Acceptance, BLA, RVT-802, Treat, Pediatric Congenital Athymia

10.Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-AL1 Study in Patients with Relapsed or Refractory Systemic Light-Chain Amyloidosis

Published: Jun 05, 2019 | Tags: Takeda, Reports, Results, Ninlaro, ixazomib, P-III, TOURMALINE-AL1 Study, Patients, Relapsed, Refractory, Systemic Light-Chain Amyloidosis

11. Bayer Signs a Research and Development Collaboration with Arvinas for its PROTAC Technology

Published: June 04, 2019 | Tags: Bayer, Signs, Research, Development, Collaboration, Arvinas, PROTAC Technology

12.BioMarin’s Vimizim (elosulfase alfa) Receives NMPA’s (CFDA) Approval for Treatment of Morquio A Syndrome

Published: June 04, 2019 | Tags: BioMarin, Vimizim, elosulfase alfa, Receives, NMPA, CFDA, Approval, Treatment, Morquio A Syndrome

13.Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019

Published: June 04, 2019 | Tags: Puma Biotechnology, Reports, Results, PB272, neratinib, P-III NALA Trial, Patients, HER2+ Metastatic Breast Cancer, #ASCO2019

14.Roche Reports Results of Venclexta/Venclyxto (venetoclax) in P-III CLL14 Study for Chronic Lymphocytic Leukemia #ASCO2019

Published: June 04, 2019 | Tags: Roche, Reports, Results, Venclexta/Venclyxto, venetoclax, P-III, CLL14 Study, Chronic Lymphocytic Leukaemia, #ASCO2019

15. Eli Lilly’s Emgality (galcanezumab-gnlm) Receives FDA’s Approval for Episodic Cluster Headache in Adults

Published: June 04, 2019 | Tags: Eli Lilly, Emgality, galcanezumab-gnlm, Receives, FDA, Approval, Episodic, Cluster, Headache, Adults

16. Astellas and Seattle Genetics Report Results of Enfortumab Vedotin in P-II EV-201 Study for Patients with Locally Advanced or Metastatic Urothelial Cancer #ASCO2019

Published: June 03, 2019 | Tags: Astellas, Seattle Genetics, Report, Results, Enfortumab Vedotin, P-II, EV-201 Study, Patients, Locally Advanced, Metastatic, Urothelial Cancer, #ASCO2019

17. Celgene and Acceleron Report FDA’s Acceptance of BLA for Luspatercept to Treat Myelodysplastic Syndromes and Beta-Thalassemia

Published: June 04, 2019 | Tags: Celgene, Acceleron, Report, FDA, Acceptance, BLA, Luspatercept, Treat, Myelodysplastic Syndromes, Beta-Thalassemia

18. Takeda Reports Results of Takhzyro (lanadelumab) in P-III HELP Study for the Prevention of Hereditary Angioedema Attacks

Published: June 03, 2019 | Tags: Takeda, Reports, Results, Takhzyro, lanadelumab, P-III, HELP Study , Prevention , Hereditary Angioedema, HAE Attacks

19. Roche Reports Results of Xofluza (baloxavir marboxil) in P-III BLOCKSTONE Study for the Prevention of Influenza

Published: June 04, 2019 | Tags: Roche, Reports, Results, Xofluza, baloxavir marboxil, P-III, BLOCKSTONE, Study, Prevention, Influenza

20.Merck’s Zerbaxa (ceftolozane and tazobactam) Receives FDA’s Approval for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia in Adults

Published: June 03, 2019 | Tags: Merck, Zerbaxa, ceftolozane, tazobactam, Receives, FDA, Approval, Hospital-Acquired, Ventilator-Associated, Bacterial Pneumonia, Adults

21. AstraZeneca and Merck Report Results of Lynparza (olaparib) in P-III SOLO3 Study for Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer #ASCO2019

Published: June 03, 2019 | Tags: AstraZeneca, Merck, Reports, Results, Lynparza, olaparib, P-III, SOLO3, Study, Platinum-Sensitive, Relapsed, Germline BRCA-mutated Advanced Ovarian Cancer, ASCO2019

22.Novartis Reports Results of Capmatinib in P-II GEOMETRY mono-1 Study for Non-Small Cell Lung Cancer with MET exon-14 Skipping Mutation #ASCO2019

Published: June 03, 2019 | Tags: Novartis, Reports, Results, Capmatinib, P-II, GEOMETRY mono-1, Study, Non-Small Cell Lung Cancer, MET exon-14 Skipping Mutation, ASCO2019

23. Novartis Reports Result of Kisqali (ribociclib) + Endocrine Therapy in P-III MONALEESA-7 Study for HR+/HER2- Advanced Breast Cancer #ASCO2019

Published: June 01, 2019 | Tags: Novartis, Reports, Result, Kisqali, ribociclib, Endocrine Therapy, P-III, MONALEESA-7, Study, HR+/HER2-, Advanced, Breast Cancer, #ASCO2019

24. Sanofi Reports Results of Isatuximab Combination Therapy in P-III ICARIA-MM Study for Relapsed/Refractory Multiple Myeloma #ASCO2019

Published: June 01, 2019 | Tags: Sanofi, Reports, Results, Isatuximab, Combination Therapy, P-III, ICARIA-MM, Study, Relapsed/Refractory, Multiple Myeloma, ASCO2019

25. Novartis Reports Results of Xolair (omalizumab) in Two P-III Studies for Chronic Rhinosinusitis with Nasal Polyps in Adults

Published: June 03, 2019 | Tags: Novartis, Reports, Results, Xolair, omalizumab, Two, P-III, Studies, Chronic Rhinosinusitis, Nasal Polyps, Adults

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post